BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced that it has enrolled its first patient in a single-center Phase 2 trial evaluating its clinical stage compound, cobiprostone, for the treatment of portal hypertension in patients with liver cirrhosis. Cirrhosis, a chronic degenerative liver disease characterized by fibrous scar tissue on the lobes, inhibits liver function and restricts normal blood flow. The obstruction in blood flow from cirrhosis is a common cause of portal hypertension.
